Heat Biologics, Inc. (NASDAQ: HBTX) is a biopharmaceutical company organzied around developing approaches to activate and co-stimulate a patient's immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. The firm's TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.offering ImPACT, an adjuvant technology to identify oncology and infectious disease indications. The firm is developing immunotherapies designed to activate a patients immune system against cancer using of CD8+ Killer T-cells. The firm's T-Cell Activation Platform (TCAP) produces therapies designed to turn cold tumors hot and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is Heat Biologics' first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patients own T-cells to attack cancer. The firm's ComPACT technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. Patients are currently (2018) being enrolled in Hat Biologics Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibbs nivolumab (Opdivo®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. We also have numerous pre-clinical programs at various stages of development.
